Buprenorphine

This session explores the clinical and policy landscape of providing medications for opioid use disorder (MOUD) in jails, prisons, and reentry settings. Dr. Arthur Robin Williams and Dr. Peter Treitler review recent research on the effectiveness of MOUD in reducing overdose and improving post-release treatment engagement. The session highlights key differences among methadone, buprenorphine, and extended-release naltrexone, including regulatory and logistical considerations unique to correctional environments. Learners will examine policy updates, case-based examples, and implementation strategies that support evidence-based treatment access. The session also addresses interdisciplinary collaboration, diversion concerns, and continuity of care across incarceration and reentry.

In this module participants review how to identify the main principles of pain treatment in opioid use disorder and to describe how these principles are applied to the treatment of acute pain as well as chronic non-terminal, non-cancer pain in OUD. Specifically, participants will learn to manage opioid withdrawal and acute pain in patients with OUD during hospitalization with and without receiving concomitant MOUD. Participants will examine strategies in formulating a multimodal pain plan for chronic pain in patients with OUD.

This activity focuses on buprenorphine for the treatment of chronic pain by reviewing different formulations and the evidence-base supporting its use for chronic pain with and without Opioid Use Disorder. Participants learn how to apply the evidence of buprenorphine’s effectiveness to different patient scenarios.

This course provides a framework for decision-making around opioid prescribing in individuals with serious illnesses such as cancer who also have a substance use disorder. Clinicians will learn factors to consider, including pain assessment, substance use history, and prognosis, and when buprenorphine might be appropriate to use as a primary medication for pain in the setting of SUD.

Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.

This manual provides guidelines for operating an opioid treatment program. It covers patient-centered care planning, assessment, admission, and monitoring; medication administration and use; medical and clinical provisions and practices; certification and accreditation; and the importance of practitioner judgment in providing care.

Provides a basic introduction of the concepts of the disease of addiction and the role of the reward system. Using neuroscience concepts as a foundation, clinical manifestations of the disease of addiction are then discussed in the form of case-based presentations. 

Outlines the basic concepts of alcohol and drug use disorders. Standard drink sizes, screening for alcohol use disorders and an introduction to alcohol withdrawal management are discussed. A basic overview of the major drug use disorders are then discussed in a clinically-relevant manner. 

Provides an overview of the history of opioid use with an overview of contributing factors to the current epidemic. Using clinical cases, opioid use disorder is then discussed in detail. Finally, there is a discussion of harm reduction approaches and treatment options.

Introduces evidence-based clinical practices of pharmacotherapy and behavioral treatments for substance use disorders. Off label medications and psychosocial support programs are also discussed.